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IHD – Ischemic Heart disease.
CHD – Coronary Heart disease
CVD – Cardio Vascular disease
IMA – Ischemia Modified Albumin
CK-MB – Creatine Kinase – MB  isoform
LDH – Lactate dehydrogenase
AST – Aspartate transaminase
ECG – Electro Cardiogram
WHO – World Health Organization
MI – Myocardial infarction
TC – Total cholesterol
TAG – Tri acyl glycerol
HDL – High density lipoprotein
VLDL – Very low density lipoprotein
LDL – Low density lipoprotein.
1INTRODUCTION
Myocardial Ischemia occurs when there is an inadequate supply of 
blood  to  the  myocardium  resulting  in  an  imbalance  between 
myocardial oxygen supply and demand.
The  most  common  cause  of  Myocardial  ischemia  is  an 
atherosclerotic disease of an epicardial coronary artery leading to 
a regional reduction in myocardial blood flow, followed by spasm, 
arterial thrombi, and rarely coronary emboli.
Episodes  of  defective  perfusion  result  in  decreased  myocardial 
tissue  oxygen  tension,  and  cause  transient  disturbance  of 
mechanical,  biochemical  and  electrical  functions  of  the 
myocardium.  More  severe  the  block,  more  the  damage  to  the 
myocardium, also in relation to the duration of oxygen supply.
Early  diagnosis  of  Myocardial  Infarction  at  this  stage  itself  can 
prevent  morbidity  and  mortality.   Though  we  have  various 
myocardial  proteins  in  the  serum  like  CK-MB,  LDH,  AST  and 
Troponins  I  and  T  for  diagnosing  Acute  Myocardial  Infarction, 
along with ECG, we should be able to identify myocardial ischemia 
2before it progresses to irreversible myocardial cell damage.  These 
markers  are  not  elevated  in  the  absence  of  necrosis  when 
measured in the first 2 to 6 hours following an ischemic event.
The present study on ischemia modified albumin has been found 
to be very useful for the detection of myocardial ischemia within 6 
hours of onset of chest pain.
Ischemia Modified Albumin (IMA) is measured by Albumin Cobalt 
Binding  assay.   It  is  based  on  the  reduced  binding  affinity  of 
human serum albumin for metal ions like Cobalt attributed to the 
free  radical  damage  to  the  N  -  terminal  region  of  albumin  in 
patients with myocardial ischemia 1.
The values are correlated with CK-MB and lipid profile.
3AIM OF THE STUDY
Aim of the study is to measure the Ischemia Modified Albumin by 
Albumin Cobalt Binding assay in patients, within 6 hours of onset 
of chest pain.
Objective :-
(1) .  To correlate the IMA values with CK-MB
(2) .  Correlation of other markers of atherosclerosis like
(a). Total cholesterol
(b).  Triacylglycerol
(c).  High density lipoprotein
(d).  Low density lipoprotein
(e).  Very low density lipoprotein with IMA
 (3). To prove the use of IMA as an early marker of myocardial 
ischemia.
4REVIEW OF LITERATURE
Ischemic Heart Disease (IHD) [CHD – Coronary Heart Disease - 
synonym] has been defined as impairment of heart function due to 
inadequate  blood  flow  to  the  heart  muscles,  compared  to  its 
needs, caused by obstructive changes in the Coronary circulation 
to heart 2.
Global burden of CHD depend on its mortality risk, decrease in life 
expectancy, increase in age specific death rates and proportion of 
death.
EPIDEMIOLOGY :-
Coronary Heart Disease is the cause of 25 – 30% of death in most 
industrialized  countries3.   At  the  beginning  of  the  twenty  first 
century, cardio vascular diseases (CVD) accounted for nearly half 
of all the deaths in the developed world and twenty five percent in 
the developing world 4.
WHO predicted  that  by  2030,  25  million  deaths  worldwide  will 
occur due to CVD annually 5.
5RISK FACTORS FOR CORONARY HEART DISEASE :-
Many prospective studies like Framingham Study established the 
Coronary Heart Disease Risk factors (i.e.) factors that make the 
occurrence of the disease more probable 6.
NON – MODIFIABLE RISK 
FACTORS
MODIFIABLE RISK 
FACTORS
Age High Blood Pressure
Sex Cigarette smoking
Family History Diabetes
Genetic Factors Obesity
Type A personality Elevated Serum Cholesterol
Sedentary Life Style
Alcohol
NON MODIFIABLE RISK FACTORS
AGE :-
Age has a dominant influence.  The peak period is between 40 to 
60 years but also occurs earlier when other risk factors co exist 6.
SEX :-
Males are more affected by IHD than females.  Clinical IHD in pre 
menopausal  women  is  very  low  due  to  estrogenic  effects. 
6However the incidence increases when oral contraceptive pills are 
used, which may precipitate hypertension 7.
After  menopause,  the  rate  of  coronary  events  accelerates  and 
equalizes to the levels observed in men 8.
FAMILY HISTORY :-
A family history of CHD (i.e.) less than 45 years in First degree 
male  relatives  and  less  than  55  years  in  female  First  degree 
relatives is known to increase the risk of premature death 9.
GENETIC FACTORS :-
The familial predisposition to atherosclerosis and Coronary Heart 
Disease  is  polygenic.   They  are  probably  the  determinants  of 
genetic derangements of lipoprotein metabolism 9 and also related 
to the clustering of other risk factors.
7PERSONALITY :-
Type A behaviour doubles the risk of Coronary Heart Disease in 
otherwise  healthy  men.   It  was  described  as  an  important  risk 
factor  in  Coronary  Disease  in  1950’s  by  Cardiologist  Meyer 
Friedman and his coworkers.
Type  A  personality  includes  a  set  of  characteristics  of  being 
impatient,  time  conscious,  insecure  about  one’s  status,  highly 
competitive, hostile and aggressive and incapable of relaxation 10.
MODIFIABLE RISK FACTORS :-
HIGH BLOOD PRESSURE :- 
Hypertension accelerates the atherosclerotic process especially if 
hyper  lipidemia is  also present.   Both the systolic  and diastolic 
components are risk factors.  There is a fivefold increase of CHD 
when the blood pressure exceeds 140/90 mm of Hg 11.
CIGARETTE SMOKING :-
The degree of risk of developing CHD is related to the number of 
cigarettes smoked per day.  Smoking accelerates atherosclerosis 
and promotes acute ischemic events 8,12.
8The mechanisms are :-
a. Carbon  monoxide  induced  atherogenesis  and  relative 
hypoxemia.
b. Nicotine stimulation of adrenergic drive increasing both heart 
rate and myocardial oxygen demand.
c. Endothelial injury and dysfunction due to nitric oxide release.
d. Enhanced  coagulability  and  induced  chronic  inflammatory 
state.
e. Development of atherogenic lipid profile (higher levels of low 
density  lipoprotein,  more  oxidized  low  density  lipoprotein, 
and lower levels of High density lipoprotein.
OBESITY :-
Greater the weight gain greater is the risk of hyper tension, CHD 
and insulin resistance diabetes mellitus.
Body mass index of  ≥  30 Kg/m2 is considered as “obesity” and it 
plays a major role in atherosclerotic progression 13, 14 .
9ELEVATED SERUM CHOLESTEROL:-
A  triangular  relationship  exists  between  habitual  diet,  blood 
cholesterol, lipoprotein levels and Coronary Heart Disease 14.
Presence  of  hyper  cholesterolemia  is  sufficient  to  initiate  the 
disease process by inducing an endothelial injury in the coronary 
arteries.   Serum  cholesterol  concentration  associated  with  low 
density lipoprotein which serves as a vehicle for  the delivery of 
cholesterol to peripheral tissues play a major role in precipitating 
CHD 15.
HDL  cholesterol  acts  as  ‘Good  Cholesterol’  against  the 
development  of  CHD  by  mobilizing  the  cholesterol  from  the 
developing atheroma and transport to liver for excretion 16, 17 .
DIABETES:-
CHD is 2-3 times higher in diabetics than in non diabetics.  It 
is responsible for 30-50% of death in diabetics over the age of 40 
years in industrialized countries 18, 19 .
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ALCOHOL:-
High alcohol intake defined as 75g or more per day becomes an 
independent risk factor for CHD 20.
PHYSICAL ACTIVITY:-
Sedentary life style with reduced physical activity leads to an early 
development of CHD.
Regular physical exercises increase the concentration of HDL and 
decrease  both  body  weight  and  blood  pressure  which  are 
beneficial to cardiovascular health 5.
ASYMPTOMATIC VERSUS SYMPTOMATIC IHD:-
In asymptomatic patients only the exercise stress tests may show 
evidence of myocardial ischemia.
In  symptomatic  phase,  the  patient  may  exhibit  a  stable  or 
progressive  course  characterized  by  chest  discomfort  (Anginal 
chest pain) 9.
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CLINICAL TYPES OF IHD:-
Patients with IHD fall into two large groups.
1. Patients with chronic coronary artery disease.
2. Acute coronary syndromes.
CHRONIC CORONARY ARTERY DISEASE:-
These patients commonly present with ANGINA PECTORIS where 
the ischemia causes pain  but  is  insufficient  to  lead to  death of 
myocardium.
Angina may be of different types.
STABLE ANGINA :-
When  the  episodes  are  provoked  by  exertion,  emotion  and 
relieved by rest due to fixed atheromatous stenosis of one or more 
coronary arteries 21.
ECG  may  be  normal  but  sometimes  shows  ST  depression, 
especially after exercise, usually on a treadmill.
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OTHER ANGINAL TYPES :-
ANGINA DECUBITUS - Occurs  in  recumbent 
positions.
NOCTURNAL ANGINA - During sleep
STABLE EXERTIONAL ANGINA - Angina occurring predictably 
at a certain level of exertion.
UNFAMILIAR TASKS - Angina  may  also  be 
precipitated  by  heavy  meal, 
exposure to cold etc.
PRINZMETAL’S VARIANT ANGINA:-
Prinzmetal’s  variant  angina  is  described  as  a  syndrome  of 
ischemic pain that occurs at rest but not usually with exertion and 
is associated with transient ST segment elevation. This is due to 
focal  spasm of  an  epicardial  coronary  artery  leading  to  severe 
myocardial ischemia 22.
Exact cause is not known, but may be related to vasoconstrictor 
mitogens,  leukotrienes  and  serotonin  or  due  to  migraine; 
Reynaud’s phenomenon or aspirin induced asthma.
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ACUTE CORONARY SYNDROME (ACS) :-
Acute Coronary Syndrome comprises of  a  spectrum of  disease 
that encompasses ischemia with minimal myocardial damage (i.e.) 
unstable angina and Myocardial Infarction.  This infarction may be 
1. STEMI – (ST elevation myocardial infarction)
2. NSTEMI – (Non ST elevation myocardial infarction) 23
Several  scenarios  fulfill  this  broad  definition  of  the  syndrome, 
including a single episode of prolonged rest angina (at least 20 
minutes),  new  onset  of  angina  (less  than  2  months)  and 
acceleration  of  angina  (an  angina  pattern  that  becomes  more 
frequent, longer in duration, or lower in threshold) 24.
UNSTABLE ANGINA (PRE INFARCTION ANGINA):-
Unstable  angina  is  characterized  by  new  onset  or  rapidly 
worsening angina (crescendo angina), angina on minimal exertion 
or angina at rest as a result of dynamic obstruction of a coronary 
artery due to plaque rupture with super imposed thrombosis and 
spasm 25.
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MYOCARDIAL INFARCTION:-
Myocardial Infarction usually results from a marked impairment in 
blood  flow  produced  by  a  coronary  occlusion  resulting  from  a 
severe  atherosclerotic  plaque  or  from  a  thrombosis  caused  by 
platelet aggregation at the site of an unstable plaque that ruptured 
less  frequently;  embolic  phenomena  or  vasospasm  also 
precipitates MI 26.
ST - ELEVATION MYOCARDIAL ISCHEMIA (STEMI):-
Patient presents with new evidence of ST segment elevation on 
ECG and labeled as ST segment elevation Myocardial Infarction.
STEMI occurs when a coronary artery thrombosis develops 
rapidly  at  a  site  of  vascular  Injury  previously  affected  by 
atherosclerosis.
NON ST - ELEVATION MYOCARDIAL ISCHEMIA (NSTEMI) :-
Those  without  ST  segment  elevation  but  with  evidence  of 
myonecrosis  are  deemed to  have a  non ST segment  elevation 
myocardial infarction 27.
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ETIOLOGY OF ISCHEMIC HEART DISEASE:-
Causes are based on
1) Reduction in blood flow
2) Increase in oxygen demand 1.
REDUCTION IN BLOOD FLOW:-
a) Atherosclerosis  reduces  the  lumen  of  the  coronary 
arteries and limits appropriate increase in perfusion, when 
the  demand  for  flow is  augmented  as  occurring  during 
exertion or excitement.
b) Coronary  blood  flow  can  be  limited  by  spasm  as  in 
prinzmetals variant angina.
c) Arterial Thrombi
d) Coronary emboli
e) Ostial narrowing due to arteritis.
f) Other causes 4.
INCREASED MYOCARDIAL OXYGEN DEMAND IN:-
1) Severe left ventricular hypertrophy due to aortic stenosis.
2) A  reduction  in  oxygen  carrying  capacity  of  blood  as  in 
presence of carboxy haemoglobin.
PATHOGENISIS OF ATHEROSCLEROSIS
[From Kumar. V, Cotran. R, Robbins. S, Robbins basic 
pathology, edi-7, Philadelphia, 2003, Saunders, p522]
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PATHOGENISIS OF ATHEROSCLEROSIS:-
Atherosclerosis  is  a  complex  disease  that  involves  lipoprotein 
influx  and  modification,  increased  prooxidant  stress  and 
inflammatory  angiogenic  and  fibro  proliferative  responses 
intermingled  with  extra  cellular  matrix  and  smooth  muscle  cell 
proliferation resulting in the formation of atherosclerotic plaque 28.
The  overwhelming  clinical  importance  of  atherosclerosis  is 
attributed to its epidemiologic data which reflects death caused by 
IHD.
RESPONSE TO INJURY:-
The  concept  of  response  to  injury  hypothesis  considers 
atherosclerosis as a chronic inflammatory response of the arterial 
wall to the injured endothelium 29, 6.
COURSE OF ATHEROSCLEROSIS:-
Chronic  endothelial  injury  due  to  toxins  from  smoking, 
hypertension,  hyperlipedemia,  hemodynamic  factors  (i.e.)  at 
branch points  lead to  endothelial  dysfunction  causing increased 
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permeability and accumulation of lipoproteins in the intima of the 
vessel wall 30, 31.
Oxidative modification of  these accumulated plasma lipoproteins 
(LDL) associated with proteoglycans occur within the intima of the 
arteries, forming fatty streak 32.
When it  contacts blood, such modified lipoprotein trigger a local 
inflammatory  response  signaling  the  migration  of  monocyte 
derived macrophages and lymphocytes converting them to foam 
cells, mediated by cytokines like IL-I(Interleukin-I) and TNF (Tumor 
necrosis factor) 33, 34.
VCAM-I  (Vascular  cell  adhesion  molecule)  in  particular  binds 
monocytes and T cells.  Activated  leukocytes and vascular wall 
cells  release  growth  factors  35,36 (Growth  factors  like  platelet 
derived growth factor, fibro blast growth factor, transferring growth 
factor)  that  promote SMC(Smooth  muscle  cell)  proliferation and 
Extra cellular matrix synthesis(ECM)  converting it  into a mature 
atheroma  and  contribute  to  the  progressive  growth  of 
atheromatous plaques, forming lesions 37,38.
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ACUTE CHANGES OF PLAQUE:-
The initiating events that disrupts a plaque are
1) Rupture,  fissuring or  ulceration of  plaques exposing highly 
thrombosed  plaque  constituents  or  underlying  sub 
endothelial basement membrane.
2) Hemorrhage  into  the  core  of  plaques  with  expansion  of 
plaque volume and worsening of the limited occlusion 39, 22.
ROLE OF THROMBUS:-
Rupture of plaques fibrous cap causes thrombosis that leads to 
episodes of unstable angina 40.
Disruption  of  atherosclerotic  plaque  commonly  causes  arterial 
thrombosis  by  allowing  blood  coagulant  factors  to  contact 
thrombogenic collagen found in the arterial  Extra Cellular Matrix 
and tissue factor produced by macrophage derived foam cells in 
the lipid core of lesion. Thus the sites of plaque rupture form the 
nidus for thrombi.
CLINICAL TYPES OF ISCHEMIC HEART DISEASE
[From Kumar. V, Cotran. R, Robbins. S, Robbins basic pathology, edi-7, 
Philadelphia, 2003, Saunders, p574]
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PATHO PHYSIOLOGY OF IHD :-
The extent of damage to myocardium and the irreversibility of the 
ischemic cardiac muscle depend on
1) The metabolic needs of the under perfused tissue.
2) Degree of existing collateral vessels. 
3) Location,  severity,  duration  and  rate  of  development  of 
arterial occlusion 41.
STABLE ANGINA :-
A lesion obstructing 70-75% or more of the vessel lumen causes 
symptomatic angina especially during increased demand.
A fixed stenosis of 90% can lead to diminished flow of blood even 
at rest 22.
ACUTE CORONARY SYNDROME (ACS) :-
The  initiating  event  precipitating  ACS  is  the  alteration  in 
structure of plaque leading to the development of a thrombus on 
top  of  an  ulcerated  or  cracked  atherosclerotic  plaque.  If  the 
ensuring thrombus is transiently occlusive, the episode of plaque 
disruption may result in episodic ischemic symptoms with minimal 
myocardial damage (unstable angina) 26.
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Acute myocardial infarction results from a severe atherosclerotic 
plaque occluding the coronary artery or from a relatively persistent 
thrombus over the ruptured plaque.  It can be regional or diffuse. 
Regional  Infarction  is  subdivided  into  transmural  and  sub 
endocardial 42.
Infarction spreads from the sub endocardial zone to the epicardium 
over a period of 4-6 hrs.  Restoration of blood flow within this time 
will prevent a transmural infarct.
The  introduction  of  thrombolytic  therapy  for  patients  with 
myocardial  ischemia will  reduce the infarct  size,  provided if  the 
occlusion is due to thrombus, if the thrombus can be dissolved and 
if the occlusion has not been present for more than a few hours 9.
Animal experiments had also proved that reperfusion even up to 6 
hours  of  coronary  occlusion,  resulted  in  a  smaller  infarct  size, 
especially in the epicardium favouring early therapy to preserve 
ventricular function and to improve survival in myocardial ischemic 
patients26.
STRUCTURE OF ALBUMIN
From Wikipedia – free encyclopedia
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ALBUMIN:-
Albumin  is  the  most  abundant  low  molecular  weight  globular 
protein  in  plasma,  60%  of  which  occupies  the  extravascular 
space43.
STRUCTURE:-
Albumin has a single polypeptide chain of 585 Amino acids, 35 
cysteine residues, 34 of which forming 17 intra chain S – S bonds. 
The free SH group at position 34 of cysteine takes part in forming 
an  inter  molecular  disulfide  linkage44 .N-  Terminal  end  has  an 
Amino acid sequence of DAHK (Aspartic acid, Alanine, Histidine, 
Lysine) 45,46
BINDING SITES:-
 Site - I binds salicylates, Sulfanomides
 Site II – Tryptophan, thyroxine, octanoate
 Imidizole of His 3- forms a binding site for cu++ ions
 N terminal- binds metal ions like cobalt, nickel, copper 44.
BINDING SITES OF ALBUMIN
From Wikipedia – free encyclopedia
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PROPERTIES:-
Albumin  is  a  stable  protein  with  high net  negative  charge.   It’s 
soluble in water.  It has a plasma half life of 15-19 days47.
METABOLISM:-
Albumin is synthesized by the hepatic parenchymal cells except in 
fetal life, where yolk sac is the primary site. Catabolism occurs by 
pinocytosis  by all  tissue and the resulting free amino acids are 
utilized for synthesis of cellular proteins.  Small amounts are also 
lost into the gastro intestinal tract and the glomerular filtrate 43.
FUNCTION:-
1) Primary function is to maintain colloid oncotic pressure48.
2) Able to bind and transport a large number of compounds 
like  cholesterol,  metallic  ions,  amino  acids,  drugs, 
hormones and bilirubin.
3) Acts as an amino acid source for peripheral tissue.
4) Albumin is an important component of plasma antioxidant 
activity.
5) It has buffering effect 49.
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6) Increases  capillary  permeability  to  small  proteins  by 
binding to endothelial membrane associated glycoprotein.
7) Albumin reduces the inflammatory response of  platelets 
and neutrophils by inhibiting leukotrienes 50.
8) It  is  essential  for  the  metabolism  and  detoxification  of 
many compounds.
CLINICAL SIGNIFICANCE:-
INCREASED PLASMA LEVELS:-
Occur as a consequence of dehydration due to reduced plasma 
water  content  leading  to  a  general  increase  in  plasma  protein 
content.
Synthetic rate and intravascular-extra vascular shifts usually occur 
fairly rapidly to stabilize relative osmotic pressure 43.  
DECREASED PLASMA LEVELS:-
1) Due to reduced synthesis as in liver disease 51.
2) Increased loss - in urine in nephrotic syndrome 52, 53
- Into intestine in protein losing enteropathy.
- From the skin in burns.
- In severe hemorrhage.
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3. Impaired uptake in malnutrition.
4. Defective digestion or malabsorption 54,55.
ANALBUMINEMIA:-
It’s an inherited condition of plasma albumin with levels less than 
0.5g/L43.
REFERENCE LEVELS:-
35   to 52 g/l or
3.5 to 5.2 g/dl.
From Wikipedia – free encyclopedia
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ISCHEMIA MODIFIED ALBUMIN:-
In  ischemia  of  the  myocardium  within  seconds  of  vascular 
obstruction, aerobic glycolysis ceases in the myocytes, leading to 
inadequate production of adenosine triphosphate and depletion of 
creatine  phosphate  resulting  in  the  accumulation  of  lactic  acid, 
NADH and fall in pH 8.
Cellular  proteins  and  enzymes  become  progressively  more 
dysfunctional as the pH falls.  Depletion of ATP leads to reduction 
in the activity of the plasma membrane dependent sodium pump 
resulting  in  intracellular  accumulation  of  sodium  and  efflux  of 
potassium. Failure of the calcium pump leads to influx of calcium 
and its damaging effects 56,57.
Reduced  pH leads  to  release  of  bound  copper  and  iron  from 
protein and intracellular stores. Ischemia also reduces the electron 
carriers,  thereby  leading  to  the  formation  of  reactive  oxygen 
species like super oxide anions 6,58,59.
These free radicals oxidatively damage the histidine present in the 
amino  terminal  region  of  albumin.   This  albumin  which  has  a 
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damaged  amino  terminal  is  called  Ischemia  Modified  Albumin 
(IMA) 60,61.
Normal albumin has a binding affinity for transitional metals like 
cobalt at its amino terminal.  But Ischemia Modified Albumin lacks 
its ability to bind to cobalt which forms the basis for Albumin cobalt 
binding  assay  in  measuring  Ischemia  Modified  Albumin  in 
myocardial ischemia 62.
IMA starts increasing within 6 to 10 minutes of ischemia, reaches a 
peak  by  4  hrs  and  returns  to  baseline  after  6  hrs  in  transient 
ischemic  conditions,  like  after  Percutaneous  transluminal 
angioplasty.   Whereas  the  N-Terminal  oxidative  damage  to 
albumin is cumulative and the repair is slow in cardiac ischemia, 
and the level also will not raise after 6 hours 59,63.
ISCHEMIA MODIFIED ALBUMIN:-
One  Ischemia  Modified  Albumin  unit  (IMA  Unit)  is  defined  as 
“Microgram of free Cobalt in the reaction mixture per ml of Serum 
sample”.
Normal values range from 6 – 80 u/ml.
RELATIONSHIP AMONG ACUTE CORONARY SYNDROME, INFLAMMATION, 
ISCHEMIA AND CHRONIC HEART FAILURE WITH ATHEROSCLEROSIS
From Update on Cardiac markers by Eileen Carreiro – Volume 37, No.10 
October 2006, lab medicine
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COBALT :-
Cobalt is an essential element for humans only as an integral part 
of vitamin B12 as a cofactor.  No other function for Cobalt in human 
body is known.
Free Cobalt (non vitamin B12) does not interact with body vitamin 
B12 pool.   Intestinal  micro flora cannot use Cobalt  to synthesize 
physiologically active Cobalamine.
Deficiency:  Cobalt deficiency has not been reported in humans.
Cobalt  excess:   Occupational  over  exposure  to  metal  alloys 
containing  Cobalt  can  lead  to  interstitial  lung  disease, 
cardiomyopathy and renal failure.
Cobalt  is  quantified  in  biological  tissues  by  atomic  absorption 
spectrometry43.
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MATERIALS AND METHODS:-
The  study  was  conducted  after  getting  the  approval  from  the 
ethical committee of Stanley Medical College.  Hundred subjects 
were chosen for the study.   Both males and females in the age 
group of 30-70 years were included and an informed consent was 
obtained from all of them.
Fifty subjects with normal, clinical, biochemical parameters   and 
with normal ECG served as the control group.  They were selected 
from the master health check up outpatient department of Stanley 
Medical College.
Fifty subjects who were admitted in Intensive coronary care unit 
[ICCU] with complaints of chest pain (of < 6 hours duration), with 
Electro cardio graphic findings showing ST changes formed the 
study  group  and  they  were  selected  from  the  department  of 
cardiology, Stanley Medical College.
INCLUSION CRITERIA:-
1) Patients admitted with complaint of chest pain within 6 hours 
of onset.
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2) Electro cardio graphic findings showing abnormal ST-T wave 
changes  (ST  segment  elevation  or  depression  or  deep 
symmetrical T wave inversion).
EXCLUSION CRITERIA:-
1) Presence of renal diseases.
2) Presence of cirrhosis,
3) Presence  of  stroke,  skeletal  muscle  injury,  malignancy, 
trauma.
4) Critically ill patients.
5) Ongoing infectious diseases.
6) Serum albumin <  2 gms/dl ,
Serum creatinine > 3 mgs/dl.
BLOOD COLLECTION:-
5ml of blood samples were collected by vene puncture with strict 
aseptic precaution as soon as the subjects got admitted as per the 
inclusion criteria.
The samples were centrifuged and serum separated.  One part of 
the  sample  was  taken  and  analysis  of  CK-MB,  albumin  and 
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creatinine were done immediately.  Remaining part of the sample 
was stored for analysis of Ischemia Modified Albumin at 20o C.
12-14 hours fasting sample was also collected from all  subjects 
during  their  hospital  stay  and  analysis  of  total  cholesterol, 
triacylglycerol and high density lipoprotein were done.
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ESTIMATION OF ISCHEMIA MODIFIED 
ALBUMIN
The  tests  were  performed  by  chemical  method  using  Cobalt 
chloride  (hexa  hydrate  form)  Dithiothreitol  and Sodium chloride. 
All the chemicals were of Analytical reagent grade purchased from 
SIGMA Chemicals.
PRINCIPLE :-
Free Cobalt that does not bind to the Ischemia modified albumin in 
serum  gives  a  brown  coloured  complex  with  Chromogen 
dithiothreitol which is measured spectrophotometrically at 470 nm.
Intensity of the colour is directly proportional to Ischemia modified 
albumin in serum.
REAGENTS :-
Cobalt chloride - 1 gm / litre
Dithiothreitol - 1.5 gm / litre
Sodium chloride - 9.0 gm / litre
All reagents are freshly prepared.
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STANDARDIZATION OF THE PROCEDURE:-
Preparation  of  standards -  Cobalt  chloride  [CoCl2.6H2O]  was 
used for preparation of cobalt standards.
STOCK SOLUTION:-  [1 gm % of cobalt]
Dissolve 0.183 mgs of cobalt chloride in deionised water and make 
up to 100ml.
SUBSTOCK:-  [10,000 µg/10 ml of cobalt] 
100 µl of stock solution is made up to 10ml.
WORKING STANDARDS:-
Working standards of various concentrations were prepared from 
the sub stock solution as shown in table.
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Working standard 
concentration
(µg/dl)
Stock solution
(µl)
Deionised water
(µl)
10 10 990
30 30 970
60 60 940
90 90 910
120 120 880
REAGENTS:-
1) COBALT CHLORIDE :-
0.183 mgs of Cobalt chloride dissolved in 100ml of deionised 
water.
2) DITHIOSTHREITOL [DTT]:-
1.5  gm  of  Dithiothreitol  dissolved  in  .1  litre  of  deionised 
water.
3) 0.9 gms % SODIUM CHLORIDE:-
9.0 grams of Sodium chloride dissolved in 1 litre of deionised 
water to quench the reaction.
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PROCEDURE:-
Test Standard Blank
Sample 200µl - -
Standard
)Cobalt chloride(
50µl 50µl 50µl
Deionised water - 200µl 250µl
DTT 50µl 50µl -
0.9% NaCl 1ml 1ml 1ml
Add 50µl of cobalt chloride to the serum sample, mix vigorously 
and after ten minutes of incubation add 50 µl of Dithiothreitol. Wait 
for 2 minutes and then add 1ml of 0.9 % sodium chloride.
Read the absorbance at 470 nm after 1 minute.
ABSORBANCE OF COBALT STANDARDS:-
Reagent blank = 0.030
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Concentration of 
working standard
(µg/dl)
Standard 
absorbance
Standard –Reagent 
blank absorbance
10 0.132 0.102
30 0.331 0.301
60 0.629 0.599
90 0.942 0.912
120 1.229 1.199
CALCULATION:-
 
Absorbance of unknown
Absorbance of standard
x concentration of standard
REFERENCE VALUES:-
6 – 80units/ml.
Cobalt (µg / dl) = [Ischemia modified albumin units/ml]
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ESTIMATION OF SERUM (CK-MB)
The tests are performed in reagent kit by Modified IFCC method. 
PRINCIPLE OF THE METHOD:-
This  procedure  involves  measurement  of  CK  activity  in  the 
presence of an antibody to CK-M monomer.
This antibody completely inhibits the activity of CK-MM and half of 
the activity of CK-MB while not affecting the B subunit activity of 
CK-MB and CK-BB.  Then the CK method is used to quantitatively 
determine  CK-B  activity.  The  CK-MB  activity  is  obtained  by 
multiplying the CK-B activity by two.
Creatine phosphate + ADP creatine   kinase Creatine + ATP
ATP + D-Glucose hexokinase Glucose-6-phosphate +ADP
Glucose-6-phosphate + NADP + 
6 - Phospogluconate + NADPH + H+
Glucose 6 Phospate dehydrogenase
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REAGENTS:-
REAGENT I:- (Buffer / Enzymes)
REAGENT II:- (Polyclonal Antibody
WORKING REAGENT:-
Add 4ml of reagent I to one ml of reagent II.  Mix gently by swirling 
till completely dissolved.
PROCEDURE:-
The reagent and sample are brought to room temperature.
To 1 ml of working reagent add 50 µl of sample and read 
immediately at 340 nm
Blank Standard Test
Reagent 1 mL 1 mL 1 mL
Standard -- 50 µL --
Sample -- -- 50µL
NORMAL VALUES:-
Serum:  0 – 24 u /L.
QUANTITATIVE DETERMINATION OF 
SERUM CREATININE
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[MODIFIED JAFFE’S KINETIC METHOD]
PRINCIPLE OF THE METHOD:-
Creatinine present in the sample reacts with picric acid in alkaline 
medium forming creatinine picrate (red coloured complex) which is 
measured at    490 nm.
REAGENTS:-
Saturated picric acid - 10 ml.
0.75 NaOH - 10ml.
Distilled  water - 20 ml.
All reagents are mixed to prepare the working reagent.
PROCEDURE:-
 Add 1 ml of working reagent to 100 µl of sample at 370C. 
Mix and read at 490 nm
Blank Standard Test
Reagent 1 mL 1 mL 1 mL
Standard -- 100 µL --
Sample -- -- 100µL
Normal values:  0.8 – 1.2 mg /dl.
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QUANTITATIVE DETERMINATION OF 
ALBUMIN:-
(BCG DYE BINDING METHOD):-
PRINCIPLE OF THE METHOD:-
Albumin in a buffered solution reacts with the anionic bromo cresol 
green (BCG) with a dye binding reaction to give a proportionate 
green colour which is measured at 630 nm (600 – 650 nm).
REAGENTS:-
Reagent I -   Bromocresol green
Succinic acid -   94 m mol /L
Sodium hydroxide -  10.2 m mol /L
BCG :-  0.149 m mol /L.
PROCEDURE:-
The samples and the reagent were brought to room temperature 
before use.
Add 1 ml of reagent to 10 µl of sample, mix incubate for 1 minute 
at room temperature, and read at 630 nm.
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Blank Standard Test
Reagent 1 mL 1 mL 1 mL
Standard -- 10 µL --
Sample -- -- 10µL
Normal values = 3.5 – 5 g / dl.
ESTIMATION OF TOTAL CHOLESTEROL:-
The  tests  are  performed  in  the  reagent  kit  by  ENZYMATIC 
CHOLESTEROL ESTERASE METHOD.
PRINCIPLE;
The  free  cholesterol  liberated  from  the  cholesterol  esters  by 
cholesterol  esterase  is  oxidized  by  cholesterol  oxidase  to 
cholestenone  with  the  simultaneous  production  of  hydrogen 
peroxide.  The hydrogen peroxide reacts with 4 – amino antipyrine 
and a phenolic compound in the presence of peroxidase to yield a 
red coloured complex.
Cholesterol + H2OCholesterol  esterase  Cholesterol + Fatty
acid
Cholesterol + O2Cholesterol  oxidase  Cholestenone + H2O2
H2O2  + 4 - aminoantipyrine + Phenolic Compound
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Peroxidase Quinone imine dye + H2O
The  concentration  of  cholesterol  in  the  sample  is  directly 
proportional to the intensity of the red coloured complex which is 
measured at 500nm.
REAGENTS;
Reagent 1 (Enzymes / Chromogen)
Reagent 1A (Buffer)
STANDARD:-
Cholesterol 200 mg / dL
RECONSTITUTED REAGENT:-
Dissolve the contents of one bottle of reagent 1 with one bottle of 
reagent 1A.
PROCEDURE:-
Blank Standard Test
Reagent 1 mL 1 mL 1 mL
Standard -- 10 µL --
Sample -- -- 10µL
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Incubate for 5 minutes at 370C.Read at 500 nm
NORMAL VALUES;
150-220mgs/dl
ESTIMATION OF TRIACYLGLYCEROL:-
The  tests  are  performed  in  the  reagent  kit  by  ENZYMATIC 
COLORIMETRIC METHOD.
PRINCIPLE:-
Lipoprotein  lipase  catalyzed  hydrolysis  of  triglycerides  yield 
glycerol which is phosphorylated by Glycerol kinase using ATP to 
glycerol  3  phosphate  which  upon  oxidation  yields  dihydroxy 
acetone  phosphate  and  hydrogen  peroxide.   The  hydrogen 
peroxide reacts with phenolic compound and 4-amino antipyrine to 
form a complex coloured.
Triacylglycerol + H2OLipase  Glycerol + Free Fatty acids
Glycerol + ATPGlycerol  kinase    Glycerol 3 Phosphate + ADP
Glycerol 3 Phosphate + O2Glycerol  phosphate  oxidase   DAP + H2O2
H2O2+4 – Amino antipyrine +DHBSPeroxidase Quinoneimine dye
+ H2O
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DAP    – Dihydroxy acetone phosphate
DHBS - 3,5 Dicholoro 2 – hydroxyl benzene sulfonate
The intensity  of  the purple coloured complex formed during the 
reaction is directly proportional to the triacylglycerol concentration 
in the sample and it is measured at 500 nm.
REAGENTS:-
REAGENT 1 (Enzymes / Chromogen)
REAGENT 1A (Buffer)
STANDARD:-
Triacylglycerol- 200 mg / dL.
RECONSTITUED REAGENT:-
Dissolve the contents of one bottle of reagent 1 with one bottle of 
reagent 1 A.
PROCEDURE:-
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Blank Standard Test
Reagent 1 mL 1 mL 1 mL
Standard -- 10 µL --
Sample -- -- 10µL
Mix well and incubate for 5 minutes at 370C.and read at 500 nm.
NORMAL VALUES;
Male;-60-150 mg/dl
Female;-40-140 mg/dl
ESTIMATION OF HIGH DENSITY LIPOPROTEIN:-
The  tests  are  performed  in  the  reagent  kit  by 
PHOSPHOTUNGSTATE METHOD.
PRINCIPLE:-
Chylomicrons, very low density lipoprotein, low density lipoprotein 
fractions  in  serum  or  plasma  are  separated  from  high  density 
lipoprotein (HDL) by precipitating with phosphotungstic acid and 
magnesium chloride.   After  centrifugation,  the cholesterol  in  the 
HDL fraction, which remains in the supernatant, is assayed with 
enzymatic  cholesterol  method,  using  Cholesterol  esterase, 
Peroxidase method.
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REAGENTS:-
REAGENT 1 (Enzymes / Chromogen)
REAGENT 1A (Buffer)
REAGENT 2 (Precipitating Reagent)
Phosphotungstic acid 50 m mol / L
Magnesium Chloride 39 m mol /L
STANDARD:-
HDL Cholesterol- 50 mg / dL.
PROCEDURE:-
1. Precipitation
Dispense into centrifuge tubes.
Test
Sample 200 µL
Precipitating reagent 200 µL
Mix well.  Centrifuge at 3500 – 4500 rpm for 10 minutes.  Separate 
the clear supernatant immediately and determine the cholesterol 
content.
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PROCEDURE:-
Blank Standard Test
Reagent 1 mL 1 mL 1 mL
Standard -- 10 µL --
Sample -- -- 10µL
Mix well and incubate for 5 minutes at 370C.and read at 500 nm
NORMAL VALUES: 40-70 mgs/dl
CALCULATED PARAMETERS:-
FRIEDWALD’S FORMULA:
VERY LOW DENSITY LIPOPROTEIN:  Triacylglycerol5  
LOW DENSITY LIPOPROTEIN:
Total Cholesterol – HDL – Triacylglycerol5
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RESULTS AND STATISTICAL ANALYSIS
A total of 100 patients were included in the present study.  Out of 
the 100, 50 were study group [IHD patients within 6 hours of onset 
of Chest pain] and other 50 were controls [Normal individuals].
AGE  DISTRIBUTION  AMONG  THE  STUDY  AND  CONTROL 
GROUP :-
Male and Female patients in the age group of 35 years to 70 years 
were taken in the study.  Both the study and control group were 
age matched.
The mean age of the control group is 51.48 and the mean age of 
the study group is 52.04.
TABLE – I
Group N Minimum age
Maximum 
age Mean
Standard 
Deviation
Student 
independent 
‘t’ test
Control 50 35 67 51.48 8.853 P=0.09
Not 
Significant
Study 50 35 68 52.04 9.178
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Quantitative  variable  [age]  is  given  as  frequency  with  their 
percentages.
TABLE – II
Age 
[years]
Control Study Chi 
Square 
test
Number Percentage Number Percentage
Upto 40 8 16.0 8 16.0
P=0.31
Not 
significant
40 – 50 15 30.0 15 30.0
51 – 60 17 34.0 16 32.0
>61 10 20.0 11 22.0
50 100.0 50 100.0
The  serum  levels  of  total  cholesterol,  Triacylglycerol  and  High 
density lipoprotein were estimated for all the patients taken for the 
study.   Very  low density  lipoprotein  and  low density  lipoprotein 
values were calculated.
The  values  obtained  in  both  the  study  and  control  group  are 
presented in the master chart I & II.
Mean and standard deviation were calculated for the quantitative 
variables,  Total  cholesterol,  Triacylglycerol,  High  density 
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lipoprotein, very low density lipoprotein and low density lipoprotein, 
IMA & CK-MB, in both study and control group and also in male 
and female patients separately.   The values were analysed and 
the results are presented in tables 3 – 9.
Correlation  between  IMA  and  Ck-MB  were  analyzed  using 
pearson’s correlation analysis.  The results are presented in table 
10 & 11.
The Receiver operating characteristic [ROC] Curves are plotted for 
IMA and CK-MB and presented in figures I & II.
COMPARISON OF BIOCHEMICAL PARAMETERS IN 
THE STUDY AND CONTROL GROUP
TABLE – III
Parameter Group Mean Standard deviation ‘P’ value
IMA
Control
Study
38.35
88.52
13.95
26.57
P=0.001
Significant
CK-MB
Control
Study
12.32
56.50
4.23
49.21
P=0.032
Significant
Total 
cholesterol
Control
Study
166.12
208.44
17.67
37.29
P=0.04
Significant
Triacyl 
glycerol
Control
Study
125.45
128.38
24.25
16.94
P=0.058
Significant
High 
density 
lipoprotein
Control
Study
44.04
34.44
9.53
8.43
P=0.01
Significant
Low density 
lipoprotein
Control
Study
96.00
148.26
22.64
35.18
P=0.032
Significant
Very low 
density 
lipoprotein
Control
Study
24.96
25.70
4.91
3.40
P=0.05
Significant
COMPARISON OF BIOCHEMICAL PARAMETERS IN 
THE AGE MATCHED STUDY AND CONTROL GROUP
TABLE – IV
[AGE < 40 YEARS]
Parameter Group Mean Standard deviation ‘P’ value
IMA
Control
Study
40.68
98.31
17.91
21.60
P=0.001
Significant
CK-MB
Control
Study
11.00
63.37
4.65
51.20
P=0.05
Significant
Total 
cholesterol
Control
Study
177.37
229.62
10.47
39.85
P=0.02
Significant
Triacyl 
glycerol
Control
Study
122.87
134.50
23.78
24.69
P=0.07
Not 
Significant
High 
density 
lipoprotein
Control
Study
42.37
33.62
12.87
8.97
P=0.03
Significant
Low density 
lipoprotein
Control
Study
109.50
169.00
21.17
41.47
P=0.04
Significant
Very low 
density 
lipoprotein
Control
Study
24.25
27.00
5.06
4.78
P=0.11
Not 
Significant
COMPARISON OF BIOCHEMICAL PARAMETERS IN 
THE AGE MATCHED STUDY AND CONTROL GROUP
TABLE – V
[AGE 41 – 50 YEARS]
Parameter Group Mean Standard deviation ‘P’ value
IMA
Control
Study
34.80
95.33
13.42
20.27
P=0.01
Significant
CK-MB
Control
Study
12.40
52.33
4.51
55.60
P=0.04
Significant
Total 
cholesterol
Control
Study
166.46
202.80
14.54
40.69
P=0.021
Significant
Triacyl 
glycerol
Control
Study
121.13
129.13
30.74
19.02
P=0.05
Significant
High 
density 
lipoprotein
Control
Study
41.86
32.20
9.07
9.61
P=0.16
Not 
Significant
Low density 
lipoprotein
Control
Study
97.46
144.73
22.55
38.16
P=0.04
Significant
Very low 
density 
lipoprotein
Control
Study
24.33
25.73
6.07
3.95
P=0.64
Not 
Significant
COMPARISON OF BIOCHEMICAL PARAMETERS IN 
THE AGE MATCHED STUDY AND CONTROL GROUP
TABLE – VI
[AGE 51 – 60 YEARS]
Parameter Group Mean Standard deviation ‘P’ value
IMA
Control
Study
36.05
67.75
13.15
30.55
P=0.001
Significant
CK-MB
Control
Study
12.35
50.12
4.09
42.54
P=0.05
Significant
Total 
cholesterol
Control
Study
160.41
214.12
20.15
30.58
P=0.04
Significant
Triacyl 
glycerol
Control
Study
127.00
126.06
22.70
13.28
P=0.19
Not 
Significant
High 
density 
lipoprotein
Control
Study
45.29
36.00
8.63
7.78
P=0.05
Significant
Low density 
lipoprotein
Control
Study
88.70
152.75
23.41
28.66
P=0.03
Significant
Very low 
density 
lipoprotein
Control
Study
25.11
25.31
4.72
2.67
P=0.03
Significant
COMPARISON OF BIOCHEMICAL PARAMETERS IN 
THE AGE MATCHED STUDY AND CONTROL GROUP
TABLE – VII
[AGE > 60 YEARS]
Parameter Group Mean Standard deviation ‘P’ value
IMA
Control
Study
45.72
102.30
11.20
10.58
P=0.01
Significant
CK-MB
Control
Study
13.20
66.45
4.07
52.43
P=0.05
Significant
Total 
cholesterol
Control
Study
166.30
192.45
19.75
35.27
P=0.017
Significant
Triacyl 
glycerol
Control
Study
131.20
126.27
17.26
12.82
P=0.76
Not 
Significant
High 
density 
lipoprotein
Control
Study
46.50
35.81
9.21
7.58
P=0.04
Significant
Low density 
lipoprotein
Control
Study
95.40
131.45
20.27
29.66
P=0.62
Not 
Significant
Very low 
density 
lipoprotein
Control
Study
26.20
25.27
3.39
2.53
P=0.03
Significant
COMPARISON OF BIOCHEMICAL PARAMETERS IN 
THE SEX MATCHED STUDY AND CONTROL GROUP
TABLE – VIII
MALE
Parameter Group Mean Standard deviation ‘P’ value
IMA
Control
Study
35.50
92.91
12.97
23.88
P=0.01
Significant
CK-MB
Control
Study
11.53
51.55
3.99
45.61
P=0.03
Significant
Total 
cholesterol
Control
Study
164.70
205.15
17.43
32.97
P=0.04
Significant
Triacyl 
glycerol
Control
Study
120.83
123.00
26.65
16.86
P=0.16
Not 
Significant
High 
density 
lipoprotein
Control
Study
44.86
37.20
10.85
8.01
P=0.05
Significant
Low density 
lipoprotein
Control
Study
93.36
151.60
25.31
37.84
P=0.05
Significant
Very low 
density 
lipoprotein
Control
Study
24.00
26.43
5.31
3.26
P=0.07
Not 
Significant
COMPARISON OF BIOCHEMICAL PARAMETERS IN 
THE SEX MATCHED STUDY AND CONTROL GROUP
TABLE – IX
FEMALE
Parameter Group Mean Standard deviation ‘P’ value
IMA
Control
Study
42.62
92.91
14.59
23.88
P=0.04
Significant
CK-MB
Control
Study
13.50
51.55
4.39
45.61
P=0.05
Significant
Total 
cholesterol
Control
Study
168.25
205.15
18.26
32.97
P=0.04
Significant
Triacyl 
glycerol
Control
Study
132.30
123.00
18.71
16.86
P=0.03
Significant
High 
density 
lipoprotein
Control
Study
42.80
37.20
7.19
8.01
P=0.03
Significant
Low density 
lipoprotein
Control
Study
99.95
143.25
17.80
31.00
P=0.17
Not 
Significant
Very low 
density 
lipoprotein
Control
Study
26.40
24.60
3.95
3.39
P=0.14
Not 
Significant
PEARSON’S CORRELATION ANALYSIS
IMA WITH OTHER VARIABLES
TABLE – X
IMA Age CK-MB TC TAG HDL LDL VLDL
Correlation 1 0.162 0.53 0.482 0.062 0.374 0.55 0.459
Significance 
[2 tailed]
0.031 <0.001 0.004 0.06 0.001 0.002 0.56
S S S NS S S NS
CK-MB WITH OTHER VARIABLES
TABLE – XI
CK-MB Age CK-MB TC TAG HDL LDL VLDL
Correlation 1 0.127 0.53 0.321 0.008 0.17 0.342 0.009
Significance 
[2 tailed]
0.042 <0.001 0.001 0.038 0.091 0.001 0.928
S S S S NS S NS
S  -  Significant
NS - Not Significant
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DISCUSSION
The present study establishes the characterization of the IMA test 
for  its association in the early diagnosis of  Myocardial  Ischemic 
patients and its comparison with CK-MB, the common biochemical 
marker of Coronary Heart Disease.
The  ability  to  detect  ischemia  before  myocyte  destruction  is 
necessary for  earlier  and more accurate management decisions 
for the patients suspected to have Acute Coronary Syndrome.  The 
current  possible  tests  58 like  CK-MB,  serum  Troponin-I  and 
Myoglobin levels will be detected in serum, only after considerable 
myocardial  cell  death  and  necrosis  had  occurred,  which  are 
precipitating factors for morbidity and mortality 58,64.
In the present study, the mean value of IMA of 88.52units/ml in the 
study group showed a significant rise than CK-MB during the early 
hours  of  ischemia  with  a  sensitivity  of  78%.  This  study  also 
correlates  with  the  data  given  in  previous  studies  on  Ischemia 
Modified  Albumin-as  a  novel  marker  of  Acute  Coronary 
Syndrome57.
IMA / CK-MB LEVELS WITH DURATION OF CHEST PAIN
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Traditional risk factors used in the prediction of atherosclerosis are 
Total Cholesterol, Triacylglycerol and low density lipoprotein while 
High density lipoprotein is a marker of anti atherogenic potential in 
an individual.
Possible  association  of  other  modifiable  risk  factors  like 
Hypertension,  Diabetes,  Smoking  and alcohol  consumption also 
necessitates the predilection for a serious outcome.
Various  epidemiological  and  clinical  studies  have  shown  strong 
relationship  between  IMA  and  CK-MB  levels  increase  in 
relationship to duration of chest pain 57.
The present  study also shows a strong positive correlation with 
duration  of  chest  pain  which  is  depicted  in  the  bar  diagram in 
(Fig-1).  There is significant serial elevation in IMA levels from 2 
hours to 6 hours of onset of chest pain compared to the percent 
increase in CK-MB levels.
ROC curve of IMA and CK-MB reveal that the IMA curve is above 
the assay curve of CK-MB 1, 65.
IMA / CK-MB LEVELS WITH AGE GROUP
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AREA UNDER THE CURVE;
Test result variable (IMA):
Area Std error Asym  sig
Asymptomatic 
95% 
confidence 
interval
Low
bound
Upper 
bound
0.921 0.28 0.000 0.866 0.976
With an area under the curve of  0.921 and a standard error  of 
0.028, IMA showed an asymptomatic significance of 0.000 proving 
it  as  a  better  predictor  over  CK-MB,  in  diagnosing  myocardial 
ischemia.  Hence IMA is a better assay for evaluating ischemia 
before CK-MB.
The  Bar  chart  in  fig  2  shows  the  increase  in  IMA  levels  with 
relation to the age group.
When the mean values of IMA and CK-MB are compared in the 
study and control groups, a significant relationship exists between 
both the study and control groups in all age group especially in the 
age group of < 40 years, 41-50 years and > 60 years.
IMA LEVELS IN NORMAL (CONTROL) AND EXPERIMENT 
(STUDY) GROUPS
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RISK FACTOR ASSOCIATION:
Age 
group(years)
Total 
number Smoking Alcohol HT DM
<40 8 4 4 2 1
41-50 15 7 5 11 1
51-60 16 2 1 11 5
>60 11 4 1 9 7
Comparing the presence of  risk  factors,  myocardial  ischemia  in 
<40 years can be attributed to smoking and alcohol consumption in 
this age group.
Onset  of  HT  and  Diabetes  in  addition,  contributed  to  the 
precipitation of myocardial ischemia in patients over the age group 
of 40 years.
The difference in the age matched study group did not  show a 
uniform significance in  any of  the measured parameters  except 
IMA  and  CK-MB.   Mean  value  of  total  cholesterol  shows  a 
significant elevation in all age groups and in both male and female. 
Triacylglycerol is raised in the age group of 41 to 50 years.
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The decrease in High Density Lipoprotein in the age group of 41 to 
50 years shows non significance where as it is significant in other 
age groups.  Level of low density lipoprotein significantly elevated 
in<40 years, 41 to 50 years and 51 to 60 years where as VLDL is 
markedly significant in 51 to 60 years and more than 60 years age 
group.
Though there is not much elevation in the mean of the measured 
parameters in both male and female, only a slight increase occurs 
in  male  patients  compared  to  female  patients.   This  can  be 
associated to the protective effects of hormones in female patients 
before menopause.
In  the  Pearson’s  correlation  analysis,  there  is  a  significant 
correlation  noticed  between  IMA  and  CK-MB  with  age,  Total 
cholesterol and LDL.  Progressive atherosclerosis with increasing 
age leads to ischemia with super added risk factors precipitating 
the development of atherosclerosis at an early age.
Alteration in food habits and life style changes can decrease the 
effects of  modifiable risk factors over  atherosclerosis  which can 
delay the onset of ischemia.
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LIMITATIONS OF THE STUDY:
1) Albumin  Cobalt  binding  (ACB)  assay  which  is  utilized  to 
estimate  IMA  levels  in  ischemic  patients  is  based  on  the 
modification in the amino terminal region of albumin produced 
by extra cellular hypoxia, acidosis, and a free radical injury 
disruption66.  Therefore ischemia in the absence of necrosis 
may  cause  bias  towards  apparent  false  positive  Albumin 
Cobalt binding data.
2) The currently used colorimetric Albumin Cobalt binding assay 
is an indirect measurement of IMA production.  New assay 
platforms (Immuno assays) are expected to be available in 
future which may improve the specificity of IMA 66, 67.
3) Currently no reference standard exists for cardiac ischemia. A 
combination  test  of  IMA  with  CK-MB  and  Troponin  I  can 
increase  the  sensitivity  in  the  early  diagnosis  of  Acute 
Coronary Syndrome 56, 68.
4) Time at  which  blood sample  is  collected  in  relation  to  the 
onset  of  chest  pain  and  other  conditions  that  cause  false 
positive and negative results must be established69.
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CONCLUSION:
Biochemical  markers  such  as  CK-MB,  Cardiac  Troponin-I  and 
Myoglobin  are  suitable  only  for  assessing myocardial  infarction. 
The results of the present study confirm the findings of previous 
studies, that reported that the Albumin Cobalt colorimetric assay 
distinguishes  myocardial  ischemic  patients  from  non  ischemic 
patients (p<0.001)
Introduction of  IMA assay for  the first  time provides emergency 
physicians  with  an  objective  diagnostic  study  to  determine  the 
presence of myocardial ischemia completely within the control of 
the emergency department.
IMA  assay  presents  a  quantitative  accurate  laboratory 
determination of the occurrence of an Ischemic myocardial event, 
Angina of various types.
Unlike the previous laboratory parameters that identify myocardial 
damage, only after it is well established, this test (Albumin Cobalt 
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binding  assay)  helps  to  determine  which  patients  will  go  in  for 
severe occlusion.
The introduction of  IMA is  a  welcome event  and based on the 
results obtained, the present study supports the hypothesis that 
Ischemia  Modified  Albumin  is  a  useful  marker  for  the  early 
diagnosis of myocardial ischemia before any significant increase in 
CK-MB levels.
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SCOPE FOR FUTURE STUDY
IMA level estimation in outpatient department itself can be done in 
patients complaining of chest pain to rule out myocardial ischemia 
before ECG manifestation especially in unstable angina, and other 
variants  of  Angina  like  Nocturnal  Angina,  prinzmetal’s  variant 
Angina and stable exertional Angina.
It can be also used to rule out non anginal causes of chest pain.
If  these  observations  are  confirmed,  IMA  can  be  used  as  an 
outpatient  investigation  tool,  to  reduce  in  appropriate  Hospital 
Admissions of Low risk patients.
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MASTER CHART FOR STUDY GROUP
Sl. 
No. AGE SEX
Dura 
tion
IMA 
u/ml
CkMB 
U/ltr
Creat
inine 
mg/dl
Albu
min 
gm/dl
TC 
mg/dl
TGL 
mg/dl
HDL 
mg/dl
LDL 
mg/dl
VLDL 
mg/dl
1 58 F 3 84.50 18.00 0.70 3.80 238.00 139.00 30.00 180.00 28.00
2 40 F 6 106.50 96.00 0.80 4.20 258.00 114.00 39.00 196.00 23.00
3 62 F 4 110.20 138.00 0.80 3.60 216.00 124.00 47.00 144.00 25.00
4 68 F 4 98.60 56.00 0.60 3.80 192.00 106.00 34.00 137.00 21.00
5 56 F 3 94.30 114.00 0.70 3.50 213.00 132.00 46.00 141.00 26.00
6 65 F 4 88.30 30.00 0.50 4.00 144.00 137.00 26.00 91.00 27.00
7 55 F 3 38.40 46.00 0.60 3.80 200.00 117.00 36.00 141.00 23.00
8 61 F 6 114.60 12.00 0.70 3.60 227.00 114.00 41.00 163.00 24.00
9 56 F 5 118.00 4.00 0.80 4.00 189.00 119.00 22.00 143.00 24.00
10 45 F 2 122.60 8.00 0.70 3.80 222.00 126.00 33.00 164.00 25.00
11 38 F 3 56.60 22.00 0.80 4.00 151.00 103.00 36.00 94.00 21.00
12 50 F 3 92.20 10.00 0.70 3.60 192.00 115.00 36.00 133.00 21.00
13 66 F 4 106.40 12.00 0.60 3.80 185.00 122.00 36.00 125.00 24.00
14 48 F 5 112.30 16.00 0.80 4.00 189.00 180.00 22.00 131.00 36.00
15 60 F 4 95.40 154.00 0.70 3.60 259.00 114.00 39.00 196.00 23.00
16 52 F 6 82.30 66.00 0.80 3.80 202.00 104.00 52.00 129.00 21.00
17 40 F 4 79.60 52.00 0.80 3.50 216.00 124.00 47.00 144.00 25.00
18 55 F 6 98.30 78.00 0.70 3.80 178.00 124.00 40.00 113.00 25.00
19 44 F 5 116.40 81.00 0.60 3.60 172.00 113.00 41.00 108.00 23.00
20 52 F 2 42.70 18.00 0.70 3.80 260.00 133.00 41.00 192.00 27.00
21 44 M 4 122.50 90.00 0.70 3.80 166.00 134.00 22.00 117.00 27.00
22 39 M 3 98.60 15.00 0.80 4.20 276.00 176.00 20.00 221.00 35.00
23 54 M 6 28.40 28.00 0.60 3.10 189.00 119.00 33.00 132.00 24.00
24 67 M 4 112.30 136.00 0.70 3.80 194.00 134.00 37.00 130.00 27.00
25 49 M 2 52.80 18.00 0.60 4.00 227.00 136.00 22.00 178.00 27.00
26 40 M 3 117.40 45.00 0.80 3.50 236.00 136.00 33.00 176.00 27.00
27 35 M 4 114.20 52.00 0.60 3.60 241.00 125.00 22.00 194.00 25.00
28 67 M 2 108.60 24.00 0.70 3.80 203.00 120.00 40.00 139.00 24.00
29 40 M 4 120.00 175.00 0.80 3.90 201.00 165.00 33.00 135.00 33.00
30 63 M 6 102.00 80.00 0.70 4.00 264.00 143.00 43.00 192.00 29.00
31 60 M 2 60.30 12.00 0.80 3.60 241.00 133.00 31.00 183.00 27.00
32 62 M 4 98.20 36.00 0.80 3.60 144.00 137.00 26.00 91.00 27.00
33 46 M 4 89.60 28.00 0.70 3.80 299.00 144.00 51.00 219.00 29.00
34 47 M 3 85.10 10.00 0.80 3.60 213.00 132.00 46.00 141.00 26.00
35 45 M 6 89.40 142.00 0.70 3.50 251.00 123.00 27.00 199.00 25.00
36 58 M 3 28.70 56.00 0.60 3.70 179.00 160.00 31.00 116.00 32.00
37 52 M 5 96.20 8.00 0.70 3.60 226.00 127.00 38.00 163.00 25.00
38 42 M 6 97.50 165.00 0.80 3.60 189.00 119.00 22.00 143.00 24.00
39 56 M 4 35.40 38.00 0.60 3.80 177.00 134.00 30.00 120.00 27.00
40 35 M 6 93.60 50.00 0.50 3.60 258.00 133.00 39.00 192.00 27.00
41 48 M 2 98.40 14.00 0.80 3.50 135.00 145.00 33.00 73.00 29.00
42 45 M 3 110.60 20.00 0.60 3.90 205.00 101.00 37.00 148.00 20.00
43 52 M 4 38.60 98.00 0.70 3.80 260.00 133.00 41.00 192.00 27.00
44 65 M 6 79.80 56.00 0.70 3.50 178.00 141.00 24.00 126.00 28.00
45 48 M 5 86.20 27.00 0.50 4.00 238.00 139.00 30.00 180.00 28.00
46 50 M 4 94.00 138.00 0.70 3.90 170.00 111.00 40.00 108.00 22.00
47 52 M 3 46.40 22.00 0.60 3.70 227.00 114.00 41.00 163.00 23.00
48 58 M 4 96.20 42.00 0.50 3.80 188.00 115.00 25.00 140.00 23.00
49 64 M 5 106.40 151.00 0.60 3.80 170.00 111.00 40.00 108.00 22.00
50 48 M 6 60.40 18.00 0.70 3.60 174.00 119.00 21.00 129.00 24.00
MASTER CHART FOR CONTROL GROUP
Sl. 
No. AGE SEX
IMA 
u/ml
CkMB 
U/ltr
Creatinine 
mg/dl
Albumi
n gm/dl
TC 
mg/dl
TGL 
mg/dl
HDL 
mg/dl
LDL 
mg/dl
VLDL 
mg/dl
1 52 F 38.60 12.00 0.60 3.60 127.00 150.00 25.00 72.00 30.00
2 45 F 28.40 10.00 0.70 3.50 158.00 133.00 39.00 92.00 27.00
3 55 F 30.50 8.00 0.80 3.80 179.00 160.00 31.00 116.00 32.00
4 40 F 15.60 6.00 0.50 3.70 176.00 170.00 40.00 102.00 34.00
5 52 F 28.40 14.00 0.70 3.60 141.00 115.00 43.00 75.00 23.00
6 60 F 58.40 15.00 0.60 4.00 171.00 122.00 40.00 107.00 24.00
7 48 F 35.60 18.00 0.50 3.80 173.00 145.00 45.00 99.00 29.00
8 65 F 42.00 20.00 0.80 3.70 156.00 130.00 32.00 98.00 26.00
9 50 F 60.40 22.00 0.90 3.60 186.00 126.00 49.00 112.00 25.00
10 37 F 45.00 14.00 0.70 3.50 171.00 122.00 40.00 107.00 24.00
11 46 F 38.60 10.00 0.60 3.80 172.00 113.00 41.00 108.00 23.00
12 55 F 24.40 8.00 0.50 3.70 145.00 120.00 43.00 78.00 24.00
13 63 F 56.60 12.00 0.80 3.50 195.00 135.00 50.00 118.00 27.00
14 54 F 28.40 10.00 0.70 3.70 165.00 145.00 49.00 87.00 29.00
15 61 F 45.60 11.00 0.60 3.90 183.00 138.00 51.00 114.00 28.00
16 57 F 38.60 15.00 0.70 3.80 148.00 152.00 48.00 69.00 31.00
17 67 F 49.40 13.00 0.80 4.00 159.00 130.00 52.00 81.00 26.00
18 65 F 62.60 18.00 0.80 4.00 179.00 142.00 50.00 119.00 28.00
19 39 F 70.00 20.00 0.90 3.70 188.00 98.00 45.00 115.00 18.00
20 58 F 55.40 14.00 0.50 3.80 193.00 100.00 43.00 130.00 20.00
21 45 M 14.20 9.00 0.70 3.80 156.00 160.00 42.00 82.00 32.00
22 46 M 15.60 14.00 0.60 3.60 150.00 86.00 45.00 46.00 18.00
23 52 M 22.30 15.00 0.80 3.70 148.00 126.00 51.00 50.00 25.00
24 48 M 24.00 8.00 0.70 3.50 145.00 72.00 59.00 72.00 14.00
25 53 M 14.60 10.00 0.50 3.90 161.00 155.00 46.00 84.00 31.00
26 41 M 25.80 12.00 0.40 3.80 186.00 138.00 52.00 106.00 28.00
27 58 M 30.60 15.00 0.50 3.90 172.00 126.00 49.00 98.00 25.00
28 39 M 35.40 8.00 0.80 4.00 160.00 140.00 66.00 66.00 28.00
29 57 M 37.60 10.00 0.60 3.70 138.00 140.00 52.00 58.00 28.00
30 62 M 46.40 15.00 0.70 3.50 152.00 126.00 60.00 67.00 25.00
31 52 M 28.60 12.00 0.60 3.80 145.00 72.00 59.00 72.00 14.00
32 44 M 35.20 10.00 0.70 3.60 150.00 86.00 35.00 97.00 18.00
33 55 M 33.80 8.00 0.80 4.00 148.00 126.00 51.00 72.00 25.00
34 47 M 43.60 16.00 0.90 4.10 167.00 141.00 47.00 92.00 28.00
35 64 M 40.00 12.00 0.60 3.90 171.00 165.00 45.00 93.00 33.00
36 49 M 52.80 13.00 0.50 3.80 154.00 155.00 49.00 74.00 31.00
37 53 M 60.00 15.00 0.60 3.70 200.00 128.00 58.00 120.00 22.00
38 57 M 52.00 23.00 0.60 3.60 175.00 100.00 42.00 113.00 20.00
39 65 M 56.40 14.00 0.70 3.50 142.00 132.00 32.00 74.00 26.00
40 48 M 51.80 10.00 0.70 3.80 173.00 145.00 30.00 113.00 29.00
41 39 M 62.90 8.00 0.80 3.70 181.00 127.00 30.00 125.00 25.00
42 43 M 40.50 4.00 0.80 3.90 190.00 111.00 33.00 135.00 22.00
43 53 M 30.80 6.00 0.70 3.50 171.00 122.00 40.00 107.00 24.00
44 64 M 28.60 5.00 0.60 3.60 188.00 98.00 53.00 115.00 20.00
45 48 M 27.50 17.00 0.50 3.70 159.00 65.00 38.00 108.00 13.00
46 40 M 31.50 14.00 0.70 3.80 176.00 115.00 52.00 101.00 23.00
47 35 M 33.60 8.00 0.80 3.90 194.00 114.00 42.00 130.00 23.00
48 66 M 29.60 12.00 0.70 4.00 138.00 116.00 40.00 75.00 23.00
49 40 M 31.50 10.00 0.90 4.10 173.00 97.00 24.00 130.00 19.00
50 42 M 28.00 13.00 0.80 3.60 178.00 141.00 24.00 126.00 28.00
STANLEY MEDICAL COLLEGE
CHENNAI-600 001
PROFORMA
NAME :  O.P / I.P.NO :
AGE / SEX :
RISK FACTORS:    HT/  DM /  FAMILY H/O DYSLIPIDEMIA /THYROID
DYSFUNCTION
DURATION OF CHEST PAIN :
INCLUSION CRITERIA: 1)  PATIENTS ADMITTED IN ICCU WITH C/O 
CHEST PAIN 2)  ECG SHOWING   ST  ↓, ST ↑, T  ↓
EXCLUSION  CRITERIA :1)  PATIENTS WITH RENAL DISEASE
2)  SERUM CREATININE >  3
3)  STROKE / CIRRHOSIS
O / E :
PR - BP - RR -
CVS -
RS -
ABD -
CNS -
INVESTIGATION –ALBUMIN - CREATININE-            
IMA- CK-MB-                  
LIPID PROFILE
RESULT :
xg;Gjy; gbtk;
_ _ _ _ _ _ _ _ _ _ _ _ _ _  vd;Dk; ehd;> kUj;Jth; nra;Ak; 
Ma;Tf;fhf ,uj;jj;ij ghpNrhjid nra;J nfhs;s vd; KO 
kdJld; rk;kjpf;fpNwd;.
ghpNrhjid  gw;wpa  tptuq;fis  kUj;Jth;  $wf;Nfl;L 
mwpe;J nfhz;Nld;.
,g;gbf;F>
Nehahspapd; cwtpdh;
